Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormality

Cancer Genetics and Cytogenetics

Volumn 177, Issue 2, 2007, Pages 139-142

  Ida, Cristiane M ^a   Rolig, Kristen A ^b   Hulshizer, Rachael L ^b   Van Dyke, Daniel L ^b   Randolph, Jamie L ^b   Jenkins, Robert B ^b   Nascimento, Antonio G ^b   Oliveira, Andre M ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 2; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MYXOINFLAMMATORY FIBROBLASTIC SARCOMA; PRIORITY JOURNAL; SARCOMA; SURGICAL APPROACH; TISSUE SECTION;

EID: 34548497637     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2007.05.018     Document Type: Article

References (41)

1. Meis-Kindblom J.M., and Kindblom L.G. Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet. Am J Surg Pathol 22 (1998) 911-924
2. Montgomery E.A., Devaney K.O., Giordano T.J., and Weiss S.W. Inflammatory myxohyaline tumor of distal extremities with virocyte or Reed-Sternberg-like cells: a distinctive lesion with features simulating inflammatory conditions, Hodgkin's disease, and various sarcomas. Mod Pathol 11 (1998) 384-391
3. Michal M. Inflammatory myxoid tumor of the soft parts with bizarre giant cells. Pathol Res Pract 194 (1998) 529-533
4. Lambert I., Debiec-Rychter M., Guelinckx P., Hagemeijer A., and Sciot R. Acral myxoinflammatory fibroblastic sarcoma with unique clonal chromosomal changes. Virchows Arch 438 (2001) 509-512
5. Mansoor A., Fidda N., Himoe E., Payne M., Lawce H., and Magenis R.E. Myxoinflammatory fibroblastic sarcoma with complex supernumerary ring chromosomes composed of chromosome 3 segments. Cancer Genet Cytogenet 152 (2004) 61-65
6. Fletcher J.A., Kozakewich H.P., Hoffer F.A., Lage J.M., Weidner N., Tepper R., Pinkus G.S., Morton C.C., and Corson J.M. Diagnostic relevance of clonal cytogenetic aberrations in malignant soft-tissue tumors. N Engl J Med 324 (1991) 436-442
7. Kimmel D.W., O'Fallon J.R., Scheithauer B.W., Kelly P.J., Dewald G.W., and Jenkins R.B. Prognostic value of cytogenetic analysis in human cerebral astrocytomas. Ann Neurol 31 (1992) 534-542
8. ISCN 2005: an international system for human cytogenetic nomenclature (2005). In: Shaffer L.G., and Tommerup N. (Eds) (2005), S. Karger, Basel
9. Speicher M.R., Gwyn Ballard S., and Ward D.C. Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 12 (1996) 368-375
10. Jalal S.M., Law M.E., Lindor N.M., Thompson K.J., and Sekhon G.S. Application of multicolor fluorescent in situ hybridization for enhanced characterization of chromosomal abnormalities in congenital disorders. Mayo Clin Proc 76 (2001) 16-21
11. Jurcic V., Zidar A., Montiel M.D., Frkovic-Grazio S., Nayler S.J., Cooper K., Suster S., and Lamovec J. Myxoinflammatory fibroblastic sarcoma: a tumor not restricted to acral sites. Ann Diagn Pathol 6 (2002) 272-280
12. McFarlane R., Meyers A.D., and Golitz L. Myxoinflammatory fibroblastic sarcoma of the neck. J Cutan Pathol 32 (2005) 375-378
13. Jalal S.M., and Law M.E. Utility of multicolor fluorescent in situ hybridization in clinical cytogenetics. Genet Med 1 (1999) 181-186
14. Grier D.G., Thompson A., Kwasniewska A., McGonigle G.J., Halliday H.L., and Lappin T.R. The pathophysiology of HOX genes and their role in cancer. J Pathol 205 (2005) 154-171
15. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence?. Nat Rev Cancer 2 (2002) 777-785
16. Raza-Egilmez S.Z., Jani-Sait S.N., Grossi M., Higgins M.J., Shows T.B., and Aplan P.D. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res 58 (1998) 4269-4273
17. Arai Y., Kyo T., Miwa H., Arai K., Kamada N., Kita K., and Ohki M. Heterogenous fusion transcripts involving the NUP98 gene and HOXD13 gene activation in a case of acute myeloid leukemia with the t(2;11)(q31;p15) translocation. Leukemia 14 (2000) 1621-1629
18. Shimada H., Arai Y., Sekiguchi S., Ishii T., Tanitsu S., and Sasaki M. Generation of the NUP98-HOXD13 fusion transcript by a rare translocation, t(2;11)(q31;p15), in a case of infant leukaemia. Br J Haematol 110 (2000) 210-213
19. Taketani T., Taki T., Shibuya N., Ito E., Kitazawa J., Terui K., and Hayashi Y. The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15). Cancer Res 62 (2002) 33-37
20. Tien H.F., Wang C.H., Chuang S.M., Chow J.M., Lee F.Y., Liu M.C., Chen Y.C., Shen M.C., Lin D.T., and Lin K.H. Cytogenetic studies, ras mutation, and clinical characteristics in primary myelodysplastic syndrome: a study on 68 Chinese patients in Taiwan. Cancer Genet Cytogenet 74 (1994) 40-49
21. Kuiper R.P., Schepens M., Thijssen J., van Asseldonk M., van den Berg E., Bridge J., Schuuring E., Schoenmakers E.F., and van Kessel A.G. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet 12 (2003) 1661-1669
22. Davis I.J., Hsi B.L., Arroyo J.D., Vargas S.O., Yeh Y.A., Motyckova G., Valencia P., Perez-Atayde A.R., Argani P., Ladanyi M., Fletcher J.A., and Fisher D.E. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A 100 (2003) 6051-6056
23. Argani P., Lae M., Hutchinson B., Reuter V.E., Collins M.H., Perentesis J., Tomaszewski J.E., Brooks J.S., Acs G., Bridge J.A., Vargas S.O., Davis I.J., Fisher D.E., and Ladanyi M. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific Alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 29 (2005) 230-240
24. Argani P., Hawkins A., Griffin C.A., Goldstein J.D., Haas M., Beckwith J.B., Mankinen C.B., and Perlman E.J. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 158 (2001) 2089-2096
25. Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., and Arden K.C. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 47 (1998) 187-199
26. Hillion J., Le Coniat M., Jonveaux P., Berger R., and Bernard O.A. AF6q21, a novel partner of the MLL gene in t(6;11)(q21;q23), defines a forkhead transcriptional factor subfamily. Blood 90 (1997) 3714-3719
27. Chen W., Itoyama T., and Chaganti R.S. Splicing factor SRP20 is a novel partner of BCL6 in a t(3;6)(q27;p21) translocation in transformed follicular lymphoma. Genes Chromosomes Cancer 32 (2001) 281-284
28. Akasaka T., Miura I., Takahashi N., Akasaka H., Yonetani N., Ohno H., Fukuhara S., and Okuma M. A recurring translocation, t(3;6)(q27;p21), in non-Hodgkin's lymphoma results in replacement of the 5′ regulatory region of BCL6 with a novel H4 histone gene. Cancer Res 57 (1997) 7-12
29. Kurata M., Maesako Y., Ueda C., Nishikori M., Akasaka T., Uchiyama T., and Ohno H. Characterization of t(3;6)(q27;p21) breakpoints in B-cell non-Hodgkin's lymphoma and construction of the histone H4/BCL6 fusion gene, leading to altered expression of Bcl-6. Cancer Res 62 (2002) 6224-6230
30. Hunter T., and Pines J. Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79 (1994) 573-582
31. Malumbres M., and Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1 (2001) 222-231
32. Shaughnessy Jr. J., Gabrea A., Qi Y., Brents L., Zhan F., Tian E., Sawyer J., Barlogie B., Bergsagel P.L., and Kuehl M. Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma. Blood 98 (2001) 217-223
33. Nishida K., Yashige H., Maekawa T., Fujii H., Taniwaki M., Horiike S., Misawa S., Inazawa J., and Abe T. Chromosome rearrangement, t(6;14) (p21.1;q32.3), in multiple myeloma. Br J Haematol 71 (1989) 295-296
34. Taniwaki M., Nishida K., Takashima T., Nakagawa H., Fujii H., Tamaki T., Shimazaki C., Horiike S., Misawa S., Abe T., and Kashima K. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84 (1994) 2283-2290
35. Sonoki T., Harder L., Horsman D.E., Karran L., Taniguchi I., Willis T.G., Gesk S., Steinemann D., Zucca E., Schlegelberger B., Sole F., Mungall A.J., Gascoyne R.D., Siebert R., and Dyer M.J. Cyclin D3 is a target gene of t(6;14)(p21.1;q32.3) of mature B-cell malignancies. Blood 98 (2001) 2837-2844
36. Kazmierczak B., Dal Cin P., Wanschura S., Borrmann L., Fusco A., Van den Berghe H., and Bullerdiek J. HMGIY is the target of 6p21.3 rearrangements in various benign mesenchymal tumors. Genes Chromosomes Cancer 23 (1998) 279-285
37. Sornberger K.S., Weremowicz S., Williams A.J., Quade B.J., Ligon A.H., Pedeutour F., Vanni R., and Morton C.C. Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Genet Cytogenet 114 (1999) 9-16
38. Dal Cin P., Wanschura S., Christiaens M.R., Van den Berghe I., Moerman P., Polito P., Kazmierczak B., Bullerdiek J., and Van den Berghe H. Hamartoma of the breast with involvement of 6p21 and rearrangement of HMGIY. Genes Chromosomes Cancer 20 (1997) 90-92
39. Dal Cin P., Fusco A., Belge G., Chiappetta G., Fedele M., Pauwels P., Bullerdiek J., and Van den Berghe H. Involvement of the HMGI(Y) gene in a microfollicular adenoma of the thyroid. Genes Chromosomes Cancer 24 (1999) 286-289
40. Dal Cin P., De Wolf F., Klerckx P., and Van den Berghe H. The 6p21 chromosome region is nonrandomly involved in endometrial polyps. Gynecol Oncol 46 (1992) 393-396
41. Tallini G., Vanni R., Manfioletti G., Kazmierczak B., Faa G., Pauwels P., Bullerdiek J., Giancotti V., Van den Berghe H., and Dal Cin P. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest 80 (2000) 359-369